|Bid||0.3100 x 1100|
|Ask||0.3140 x 1100|
|Day's range||0.2721 - 0.3261|
|52-week range||0.2721 - 2.7500|
|Beta (5Y monthly)||1.83|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2022 - 04 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.33|
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.
BOCA RATON, Fla., December 10, 2021--TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company. In its complete response letter, the FDA provided recommendations and requested additional information that could support approval of revisions to certain manufacturin
BOCA RATON, Fla., December 08, 2021--TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively "Amneal").